In contrast, CD22, CD30, and CD123 emerge as less suited targets for immunotherapy in SM patients due to a lack of expression in a significant fraction of patients with ISM and particularly advanced forms of SM. This evidence concerns the gene CD22 and systemic mastocytosis.